|
|
Blood, 15 December 2006, Vol. 108, No. 13, pp. 3992-3996.
Prepublished online as a Blood First Edition Paper on August 17, 2006; DOI 10.1182/blood-2006-05-026112.
 Previous Article | Next Article 
Submitted May 30, 2006
Accepted August 7, 2006
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
NICOLA GIULIANI*, VITTORIO RIZZOLI, and G D ROODMAN
Cattedra e U.O. di Ematologia-CTMO, Universita Degli Studi di Parma, Parma, Italy
University of Pittsburgh School of Medicine and VA Medical Center, Pittsburgh, PA, USA
* Corresponding author; email: n_giuliani{at}yahoo.com.
Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased of osteoclast formation and activity that occur in close proximity with myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone destructive process. Recently, the biological mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Pennisi, W. Ling, X. Li, S. Khan, J. D. Shaughnessy Jr, B. Barlogie, and S. Yaccoby
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
Blood,
August 27, 2009;
114(9):
1803 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc.,
August 1, 2009;
20(8):
1303 - 1317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hiruma, T. Honjo, D. F. Jelinek, J. J. Windle, J. Shin, G. D. Roodman, and N. Kurihara
Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation
Blood,
May 14, 2009;
113(20):
4894 - 4902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Silvestris, S. Ciavarella, M. De Matteo, M. Tucci, and F. Dammacco
Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?
Oncologist,
March 1, 2009;
14(3):
264 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, and C. Pellat-Deceunynck
Osteoclasts support the survival of human plasma cells in vitro
Int. Immunol.,
June 1, 2008;
20(6):
775 - 782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
Skeletal Imaging and Management of Bone Disease
Hematology,
January 1, 2008;
2008(1):
313 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, G. Donofrio, S. Bonomini, R. Sala, M. Mangoni, and V. Rizzoli
Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment
Cancer Res.,
August 15, 2007;
67(16):
7665 - 7674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, O. Sezer, P. Croucher, and M.-A. Dimopoulos
Myeloma bone disease and proteasome inhibition therapies
Blood,
August 15, 2007;
110(4):
1098 - 1104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, S. Bonomini, M. Crugnola, C. Mancini, E. Martella, L. Ferrari, A. Tabilio, et al.
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Blood,
July 1, 2007;
110(1):
334 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
